Soria JC - Search Results

1

Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE.

Gaspar N, Marshall LV, Binner D, Herold R, Rousseau R, Blanc P, Capdeville R, Carleer J, Copland C, Kerloeguen Y, Norga K, Pacaud L, Sevaux MA, Spadoni C, Sterba J, Ligas F, Taube T, Uttenreuther-Fischer M, Chioato S, O'Connell MA, Geoerger B, Blay JY, Soria JC, Kaye S, Wulff B, Brugières L, Vassal G, Pearson ADJ; Members of Working Group 1 of the Paediatric Platform of ACCELERATE. Gaspar N, et al. Among authors: soria jc. Ann Oncol. 2018 Mar 1;29(3):766-771. doi: 10.1093/annonc/mdy002. Ann Oncol. 2018. PMID: 29351570 Free PMC article. No abstract available.

2

[Telomerase, a universal target in immunotherapy strategies against tumor?].

Rousseau R, Soria JC. Rousseau R, et al. Among authors: soria jc. Bull Cancer. 2000 Dec;87(12):895-901. Bull Cancer. 2000. PMID: 11174119 Free article. Review. French.

3

Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?

Soria JC, Brisgand D, Le Chevalier T. Soria JC, et al. Ann Oncol. 2001 Dec;12(12):1667-70. doi: 10.1023/a:1013574413217. Ann Oncol. 2001. PMID: 11843242 Free article. Clinical Trial.

4

Targeted therapies in lung cancer.

Besse B, Ropert S, Soria JC. Besse B, et al. Among authors: soria jc. Ann Oncol. 2007 Jul;18 Suppl 9:ix135-42. doi: 10.1093/annonc/mdm308. Ann Oncol. 2007. PMID: 17631566 Free article. Review. No abstract available.

5

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.

Soria JC, Massard C, Magné N, Bader T, Mansfield CD, Blay JY, Bui BN, Moussy A, Hermine O, Armand JP. Soria JC, et al. Eur J Cancer. 2009 Sep;45(13):2333-41. doi: 10.1016/j.ejca.2009.05.010. Epub 2009 Jun 21. Eur J Cancer. 2009. PMID: 19541476 Clinical Trial.

6

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

Soria JC, Massard C, Le Chevalier T. Soria JC, et al. Ann Oncol. 2010 Dec;21(12):2324-2332. doi: 10.1093/annonc/mdq204. Epub 2010 May 23. Ann Oncol. 2010. PMID: 20497965 Free article. Review.

7

ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy.

Besse B, Massard C, Haddad V, Andre F, Dunant A, Pirker R, Olaussen KA, Brambilla E, Fouret P, Soria JC. Besse B, et al. Among authors: soria jc. Ann Oncol. 2011 Mar;22(3):575-581. doi: 10.1093/annonc/mdq407. Epub 2010 Aug 26. Ann Oncol. 2011. PMID: 20801905 Free article.

8

Phase 0 clinical trials in oncology: an exploratory methodology for constructing a study with patients undergoing surgery for metastatic disease.

Pocard M, Soria JC, Aldaz-Carroll L, Bellet D. Pocard M, et al. Among authors: soria jc. J Clin Oncol. 2010 Oct 20;28(30):4551-3. doi: 10.1200/JCO.2010.29.2870. Epub 2010 Sep 13. J Clin Oncol. 2010. PMID: 20837954 No abstract available.

9

Added value of molecular targeted agents in oncology.

Soria JC, Blay JY, Spano JP, Pivot X, Coscas Y, Khayat D. Soria JC, et al. Ann Oncol. 2011 Aug;22(8):1703-16. doi: 10.1093/annonc/mdq675. Epub 2011 Feb 7. Ann Oncol. 2011. PMID: 21300696 Free article. Review.

10

Biology-driven phase II trials: what is the optimal model for molecular selection?

Andre F, Delaloge S, Soria JC. Andre F, et al. Among authors: soria jc. J Clin Oncol. 2011 Apr 1;29(10):1236-8. doi: 10.1200/JCO.2010.31.6877. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343554 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

736 results

Search Page

Filters